Collagen-targeted PET Imaging for Early Interstitial Lung Disease

Launched by MASSACHUSETTS GENERAL HOSPITAL · Jun 10, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging technique called \[68Ga\]CBP8, which helps doctors see collagen buildup in the lungs. This collagen buildup can be an early sign of interstitial lung disease (ILD), a condition that affects the tissue in the lungs and can lead to breathing difficulties. The aim is to determine how well this imaging method can detect early changes in the lungs, which can help in diagnosing and treating the disease sooner.

To participate in this study, you need to be over 40 years old and either a first-degree relative of someone with pulmonary fibrosis or someone who has early signs of ILD. You should not have a history of smoking in the past six months and must be able to give written consent to join. If you qualify, you can expect to undergo imaging tests that involve lying comfortably on a special bed inside an MR-PET machine. It’s important to note that certain medical conditions or devices, like pacemakers or severe claustrophobia, may prevent you from participating. This study is currently looking for participants, and your involvement could contribute to better understanding and treatment of interstitial lung disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Group 1: First degree relatives of a family member with pulmonary fibrosis (n=8)
• • Age greater than 40 years
• • Have the ability to give written informed consent
• • First degree relative of a family member with pulmonary fibrosis
• • No known history of interstitial lung disease
• • No tobacco use within the prior 6 months.
• • Group 2: Subjects with interstitial lung abnormalities (ILAs) or interstitial lung disease (ILD) (n=22)
• • Age greater than 40 years
• • Have the ability to give written informed consent
• • ILAs or early ILD (defined by presence of reticular markings and / or traction bronchiectasis but absence of a definite UIP pattern)
• • No tobacco use within the prior 6 months.
• Exclusion criteria:
• • Electrical implants such as cardiac pacemaker or perfusion pump
• • Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, metallic tattoos anywhere on the body, tattoos near the eye, or steel implants ferromagnetic objects such as jewelry or metal clips in clothing
• • Historical eGFR of less than 30 mL/min/1.73 m2
• • Pregnant or breastfeeding (a negative quantitative serum hCG pregnancy test is required for females having child-bearing potential before the subject can participate)
• • Claustrophobic reactions
• • Research-related radiation exposure exceeds current Radiology Department guidelines (i.e. 50 mSv in the prior 12 months)
• • Unable to lie comfortably on a bed inside the MR-PET
• • BMI \> 33 (limit of the PET-MRI table)
• • Determined by the investigator(s) to be clinically unsuitable for the study (e.g. based on screening visit and/or during study procedures)
• • Pneumonia or other acute respiratory illness within 6 weeks of study entry
• • Parenchymal lung disease except for ILD/ILAs or emphysema
• • Acute exacerbation of ILD within the prior 6 months
• • VATS within the prior 6 months
• • Prior radiation therapy to the thorax
• • Known allergy to gadolinium.